Canna~Fangled Abstracts

[Clinical pharmacology of medical cannabinoids in chronic pain].

By June 24, 2015 No Comments
2015 Jun 24;11(480):1390, 1392-4.
[Article in French]


PM 1aIn Switzerland, medical cannabinoids can be prescribed under compassionate use after special authorization in justified indications such as refractory pain. Evidence of efficacy in pain is limited and the clinical benefit seems to be modest. Their drug-drug interactions (DDI) profile is poorly documented. Cytochromes P450 (CYP) 2C9 and 3A4 are involved in the metabolism of tetrahydrocannabinol and cannabidiol, which implies possible DDI with CYP450 inhibitor and inducer, such as anticonvulsivants and HIV protease inhibitors, which may be prescribed in patients with neuropathic pain.




[PubMed – in process] 
Publication Types

Publication Types

twin memes II

en English